bs-9728R [Primary Antibody]
B4GALT7 Polyclonal Antibody
www.biossusa.com
support@biossusa.com
800.501.7654 [DOMESTIC]
+1.781.569.5821 [INTERNATIONAL]
DATASHEET

Host: Rabbit

Target Protein: B4GALT7

Immunogen Range: 201-300/327


Clonality: Polyclonal

Isotype: IgG

Entrez Gene: 11285

Source: KLH conjugated synthetic peptide derived from human B4GALT7

Purification: Purified by Protein A.

Storage Buffer: 0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.

Storage: Shipped at 4℃. Store at -20℃ for one year. Avoid repeated freeze/thaw cycles.

Background:

Beta-1,4-galactosyltransferases (beta-1,4-Gal-T) are type II membrane-bound glycoproteins that are substrate-specific and function to transfer galactose in a beta-1,4 linkage to an acceptor sugar. There are seven members of the beta-1,4-Gal-T family, all of which are directed to the golgi apparatus through a hydrophobic sequence at the N-terminus. Beta-1,4-Gal-T7, also known as B4GALT7 or XGALT1, is a 327 amino acid single-pass type II membrane protein that is expressed at high levels in heart, pancreas and liver. Beta-1,4-Gal-T7 uses manganese to catalyze the UDP-dependent biosynthesis of glycosphingolipids. The gene encoding beta-1,4-Gal-T7 is mutated in Ehlers-Danlos syndrome progeroid type (EDSP), a variant form of Ehlers-Danlos syndrome characterized by progeroid facies, mild mental retardation, short stature, skin hyperextensibility, moderate skin fragility, joint hypermobility principally in digits. Beta-1,4-galactosyltransferases (Beta-1,4-Gal-T) are type II membrane-bound glycoproteins that are substrate-specific and function to transfer galactose in a beta-1,4 linkage to an acceptor sugar.

Size: 100ul

Concentration: 1ug/ul

Applications: WB(1:300-5000)
IHC-P(1:200-400)
IF(IHC-P)(1:50-200)

Cross Reactive Species: Human
Mouse
Rat

For research use only. Not intended for diagnostic or therapeutic use.

VALIDATION IMAGES

25 ug total protein per lane of various lysates (see on figure) probed with B4GALT7 polyclonal antibody, unconjugated (bs-9728R) at 1:1000 dilution and 4°C overnight incubation. Followed by conjugated secondary antibody incubation at r.t. for 60 min.